Tirzepatide vs. Semaglutide for Weight Loss: Understanding the Differences

Two GLP-1 Medications, Different Mechanisms and Outcomes

Semaglutide (Wegovy, Ozempic) has become the most recognized GLP-1 receptor agonist for medical weight management, but it has been joined by a newer and in many metrics more potent option: tirzepatide (Zepbound for weight loss, Mounjaro for diabetes). Understanding how these medications differ — in mechanism, efficacy, side effect profile, and practical considerations — helps patients and providers make better-informed treatment decisions.

Mechanism of Action: Single vs. Dual Agonism

Semaglutide is a selective GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1, a gut hormone that stimulates insulin secretion, reduces glucagon, slows gastric emptying, and signals satiety to the brain. By activating GLP-1 receptors — particularly in the hypothalamus and brainstem — semaglutide reduces appetite, decreases food cravings, and produces significant weight loss.

Tirzepatide adds a second mechanism: it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, making it a dual GLP-1/GIP agonist. GIP is another incretin hormone that works synergistically with GLP-1 in several ways — enhancing insulin secretion, promoting fat tissue metabolism, and potentially modulating appetite regulation through pathways distinct from GLP-1 alone. This dual mechanism appears to produce additive to synergistic weight loss outcomes beyond semaglutide.

Weight Loss Outcomes: Head-to-Head Data

The SURMOUNT-1 trial of tirzepatide (Zepbound) demonstrated average weight loss of 20.9% at the highest dose (15 mg weekly) over 72 weeks — the largest weight loss outcome ever reported in a randomized pharmaceutical trial. Approximately 57% of participants achieved ≥20% body weight loss at the highest dose.

Semaglutide’s STEP 1 trial showed 14.9% average weight loss at 68 weeks. This is still a clinically remarkable outcome — far exceeding lifestyle alone — but the tirzepatide outcomes are approximately 30–40% greater in head-to-head comparisons.

The SURMOUNT-5 trial, which directly compared tirzepatide 10 or 15 mg versus semaglutide 2.4 mg, found tirzepatide produced approximately 47% greater weight loss than semaglutide over 72 weeks.

Side Effect Comparison

Both medications share similar GI side effect profiles — nausea, vomiting, constipation, diarrhea — due to their shared GLP-1 agonist activity. Tirzepatide’s tolerability profile in trials was comparable to semaglutide despite its greater potency, possibly because GIP receptor activation has independent effects that partially offset GI disruption.

The key practical difference: semaglutide is FDA-approved at 2.4 mg weekly for weight management (Wegovy), while tirzepatide was FDA-approved at doses up to 15 mg weekly for weight management (Zepbound) in 2023. Both are weekly subcutaneous injections with gradual dose escalation over several months.

Which Is Right for You?

Tirzepatide generally produces greater weight loss. Semaglutide has a longer clinical track record and broader insurance coverage (though neither is reliably covered for weight management by most commercial insurers). For patients with type 2 diabetes, both have FDA approval for glucose management, with tirzepatide showing superior HbA1c reductions alongside greater weight loss.

At Multigen Wellness, the choice between semaglutide and tirzepatide is made collaboratively — based on treatment goals, response to prior GLP-1 therapy if applicable, cost considerations, and individual clinical factors.

To discuss which medical weight loss medication is best for your situation, call Multigen Wellness at (800) 259-0015.